26 documents

Read All
23:25 , Jul 6, 2018 |  BC Extra  |  Financial News

Biotech stocks rise after positive AD data

Biotech indexes gained Friday after Biogen Inc. (NASDAQ:BIIB) and Eisai Co. Ltd. (Tokyo:4523) reported 18-month data for BAN2401 to treat Alzheimer's disease. Biogen gained $58.67 (20%) to $357.48, adding about $12.3 billion in market cap,...
Read More
03:32 , Jul 6, 2018 |  BC Extra  |  Clinical News

BAN2401 slows AD progression at 18 months

Biogen Inc. (NASDAQ:BIIB) gained $58.67 (20%) to $357.48 on Friday, adding about $12.3 billion in market cap, on new data for its Alzheimer's disease candidate BAN2401. Biogen and partner Eisai Co. Ltd. (Tokyo:4523) reported secondary...
Read More
17:04 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

Eisai, Biogen continuing AD trial of BAN2401 despite 12-month failure

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) said an IDMC determined that BAN2401 "did not meet the criteria for success" at 12 months on the primary endpoint in the Phase II Study 201 to...
Read More
21:43 , Dec 21, 2017 |  BC Extra  |  Clinical News

Eisai, Biogen continuing AD trial despite 12-month failure

Eisai Co. Ltd. (Tokyo:4523) and Biogen Inc. (NASDAQ:BIIB) said an IDMC determined that BAN2401 "did not meet the criteria for success" at 12 months on the primary endpoint in the Phase II Study 201 to...
Read More
02:00 , Oct 28, 2017 |  BioCentury  |  Strategy

Biogen doubles down

Shares of Biogen Inc. were buffeted last week by a pair of poorly understood moves intended to improve the big biotech’s share of profits for aducanumab, along with lower than expected revenues for newly launched...
Read More
18:59 , Oct 27, 2017 |  BC Week In Review  |  Company News

Eisai exercises option for Biogen's anti-beta amyeloid mAb

Eisai Co. Ltd. (Tokyo:4523) exercised an option to co-develop and co-promote aducanumab (BIIB037) from Biogen Inc. (NASDAQ:BIIB). The industry has kept a close watch on the human recombinant anti-beta amyloid mAb after it became the...
Read More
22:09 , Oct 23, 2017 |  BC Extra  |  Company News

Eisai exercises option for Biogen’s anti-beta amyloid mAb

Eisai Co. Ltd. (Tokyo:4523) exercised an option to co-develop and co-promote aducanumab (BIIB037) from Biogen Inc. (NASDAQ:BIIB). The industry has kept a close watch on the human recombinant anti-beta amyloid mAb after it became the...
Read More
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This year...
Read More
07:00 , Oct 26, 2015 |  BC Week In Review  |  Company News

Biogen autoimmune news

In its 3Q earnings, Biogen said it plans to eliminate some pipeline programs and cut 11% of its 8,000-employee workforce to push higher priority candidates through the clinic and boost marketing efforts for multiple sclerosis...
Read More
07:00 , Oct 26, 2015 |  BioCentury  |  Strategy

Against the wind

An unexpected slowing of Biogen Inc.'s key growth engine and two clinical setbacks in multiple sclerosis have led management to reallocate resources toward marketing support for Tecfidera dimethyl fumarate and simultaneous development of multiple late-stage...
Read More